Professional Documents
Culture Documents
Additional Information Handle in accordance with good industrial hygiene and safety
practices.
Avoid inhalation of dusts.
4.2 Most important symptoms Exposure to any kind of dust is potentially harmful.
and effects, both acute and
delayed
7.1 Precautions for safe handling Avoid generation of dust. Handle in accordance with good
industrial hygiene and safety practices.
See Also Section 8.
A considerable static electrical charge can be built up during
mechanical handling which may become a hazard in
atmospheres containing flammable vapours. Advice on the
control of static is given in British Standard BS 5958.
7.2 Conditions for safe storage, Keep container tightly closed and dry.
including any incompatibilities
7.3 Specific end use(s) Identified uses are described further after section 16 of this
document.
Risk management measures (RMMs) for identified uses must be implemented as described in this
SDS.
8.2 Exposure controls Wear protective equipment to comply with good occupational
hygiene practice. Do not eat, drink or smoke at the work place.
8.2.1 Appropriate engineering Engineering methods to prevent or control exposure are
controls preferred. Methods include process or personnel enclosure,
mechanical ventilation (dilution and local exhaust), and control of
process conditions.
8.2.2 Personal Protection
Inhalation Amorphous silica has little adverse effect on lungs and does not
produce significant disease or toxic effect when exposure is kept
below the permitted limits. However, existing medical conditions
(eg. asthma, bronchitis) may be aggravated by exposure to dust.
Effects of dust may be greater, and occur at lower levels of
exposure in smokers compared to non-smokers.
Skin Contact Dust may have a drying effect on the skin. Dermal LD50 (rabbit)
>5000 mg/kg bw
Eye Contact Dust may cause discomfort and mild irritation.
Skin corrosion/irritation Non-irritant. Dust may have a drying effect on the skin.
Serious eye damage/irritation Non-irritant.
Sensitisation Not sensitising.
Mutagenicity No evidence of genotoxicity. In vitro/in vivo negative.
Carcinogenicity IARC assessment: Amorphous silica is not classifiable as to its
carcinogenicity to humans (Group 3).
Reproductive toxicity No evidence of reproductive toxicity or developmental toxicity.
STOT - single exposure Not classified
STOT - repeated exposure Not classified. NOAEL oral (rat) >4000 mg/kg bw/d
Aspiration hazard Not classified
Other information Not applicable
15.2 Chemical Safety Assessment A Chemical Safety Assessment has been carried out for
this substance/mixture by the supplier.
Identified Uses
NOTE:
The following pages contain the current list of identified uses for Sorbosil synthetic amorphous
silicas manufactured by PQ Corporation.
Please note that individual applications may have specific additional regulatory requirements
therefore listing in this document does not guarantee suitability for any given application.
SORBOSIL IU - en 1 of 3
Identified Uses for SORBOSIL
Version 2 – January 2014
*Flow modifier, process regulator or aid, structure agent, viscosity control agent
SORBOSIL IU - en 2 of 3
GLOSSARY – Based on ECHA Guidance on information requirements and chemical
assessment Chapter R.12: Use descriptor system Version 2 March 2010
SORBOSIL IU - en 3 of 3